Cabometyx Receives FDA Approval for Advanced Renal-Cell Carcinoma

Online First - FDA News & Updates

On April 25, 2016, the FDA approved cabozantinib (Cabometyx; Exelixis) for the treatment of patients with advanced renal-cell carcinoma (RCC) who had received anti-angiogenic therapy. The FDA granted this approval under its fast track and priority review procedures.
           

The approval was based on 1 randomized clinical trial of patients with advanced RCC who had previously received anti-angiogenic therapy and were randomized to oral cabozantinib 60 mg daily (N = 330) or to everolimus 10 mg orally once daily (N = 328). The primary end point was progression-free survival (PFS) in the first 375 randomized patients.

The median PFS in this group was 7.4 months with cabozantinib and 3.8 months with everolimus (P <.001). The median overall survival in the full study population was 21.4 and 16.5 months, respectively. The response rate was 17% versus 3%, respectively. 

The safety of cabozantinib was evaluated in 331 patients. The most common adverse reactions included diarrhea, fatigue, nausea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, hypertension, vomiting, weight loss, and constipation. In addition, 60% of patients receiving cabozantinib had ≥1dose reduction. Serious adverse events were reported in 40% of patients; these included abdominal pain, pleural effusion, diarrhea, and nausea. The recommended dose and schedule for cabozantinib is 60 mg orally daily. 

Cabozantinib received a breakthrough therapy designation from the FDA in August 2015.

Related Items
Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL
JHOP Web Exclusives published on October 9, 2017 in FDA News & Updates, Online Only
Kymriah First Gene Therapy Approved by the FDA, Indicated for Young Patients with B-Cell ALL and CD19
JHOP Web Exclusives published on October 9, 2017 in FDA News & Updates, Online Only
Olaparib Tablet Receives New Indication in Ovarian Cancer
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in FDA News & Updates
FDA News - September 2017
JHOP Web Exclusives published on September 8, 2017 in FDA News & Updates, Online Only
FDA News - August 2017
JHOP Web Exclusives published on August 1, 2017 in FDA News & Updates, Online Only
FDA News - June 2017
JHOP Web Exclusives published on June 1, 2017 in FDA News & Updates, Online Only
Cancer Drug Approvals: A Tale of 2 Views
Sharon Donovan
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in FDA News & Updates
FDA News - April 2017: Additional Items
JHOP Web Exclusives published on April 14, 2017 in FDA News & Updates, Online Only
FDA News - April 2017
JHOP Web Exclusives published on April 1, 2017 in FDA News & Updates, Online Only
Rucaparib Approved with a Companion Diagnostic Test for Patients with Advanced Ovarian Cancer
TON - January 2017, Vol 10, No 1 published on January 12, 2017 in FDA News & Updates
Last modified: November 11, 2016